To me, its' JBM Healthcare. On the surface, its' an unknown newly floated issue. However, underneath, it represents a powerpack of legacy trusted chinese healthcare brands that has went through thick & thin with chinese people. Brand value resides in consumer's trust in them & on this scale, JBM's brands is of the highest quality.
Revisiting Warren's quote at the beginning of this write up, JBM Healthcare has used its cashflow surpluses to eliminate debt (*yes, its a zero debt company); while returning shareholder value via a stock buyback program that ended up purchasing 10% of outstanding shares & an 8% dividend so far this year. That comes up to a total of +19% shareholder return in 2024 even with Hong Kong Exchange closed for the year. Speaking of minority shareholder interest. Cheers.
Comments